&w=3840&q=100)
Anti-obesity mkt heats up as Mounjaro's Kwikpen version gets India approval
The drug, launched in March this year, was until now available only in vials rather than a ready-to-use pen. This announcement from the US-based pharmaceutical giant comes just a day after Danish firm Novo Nordisk launched Wegovy in the Indian market.
India has the third-highest number of people living with overweight and obesity. According to the India Diabetes (INDIAB) study, the country has 254 million people with generalised obesity and 351 million with abdominal obesity.
The anti-obesity market, while limited, has seen a surge in India in recent times.
According to data from market research firm Pharmarack, sales of Mounjaro rose 60 per cent in May—its second full month since launch. The drug recorded value sales worth ₹12.61 crore in May, compared to ₹7.88 crore in April.
Wegovy is expected to be available in pharmacies across India by the end of June 2025.
Mounjaro is currently available in just two dose strengths—2.5 mg and 5 mg—priced between ₹14,000 and ₹17,500 per month. In contrast, Wegovy will be available in five dose strengths—0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and a maintenance dose of 2.4 mg—at a monthly price of ₹17,345–26,050.
Like Mounjaro, Wegovy follows a gradual dose-escalation protocol to minimise gastrointestinal side effects and improve tolerability. 'Patients typically begin with a 0.25 mg dose of semaglutide once weekly for four weeks, followed by incremental increases every month until reaching the maintenance dose of 2.4 mg,' an official said.
Officials at Lilly indicated that with the introduction of the Kwikpen version, Mounjaro will soon be available in six dose strengths (one more than Wegovy): 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
'With this approval, all six dosage options for Mounjaro (tirzepatide) will soon be available in India, supporting a more personalised approach to treatment and allowing healthcare professionals to tailor care based on individual patient needs and clinical goals,' said Winselow Tucker, president and general manager at Lilly India.
Commenting on the growing competition, Sukhvinder Singh Saggu, director for Minimal Access, GI and Bariatric Surgery at CK Birla Hospital, Delhi, said that the entry of global pharmaceutical giants such as Eli Lilly and Novo Nordisk into India's obesity market will likely drive innovation, improve accessibility, and potentially bring down costs over time.
'With both Mounjaro (tirzepatide) and Wegovy (semaglutide) showing promising clinical outcomes, the increased options could encourage broader adoption of medical interventions for obesity, which has long been under-treated in India,' he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
32 minutes ago
- The Hindu
Hyderabad NGO adopts Tamil Nadu's doorstep NCD model in slums
Hyderabad-based Helping Hand Foundation (HHF) has launched a community health outreach programme modelled on Tamil Nadu's Makkalai Thedi Maruthuvam scheme. The initiative aims to bring doorstep Non-Communicable Disease (NCD) screening, consultation and medicine delivery, to vulnerable residents of Rajendranagar mandal. The programme has begun operations through three newly-established NCD sub-centres in Mir Mahamod Pahadi Colony, Suleman Nagar, and Chintalmet, all under the jurisdiction of Rajendranagar Primary Health Centre (PHC). These areas, home to nearly 65,000 to 70,000 people from low-income households, have long struggled with poor access to healthcare. Each sub-centre is staffed with a doctor, a nurse, and three to four trained Community Health Workers (CHWs), with each CHW responsible for covering 200 to 250 households. Their duties include door-to-door screening for blood pressure, blood sugar, and body mass index (BMI) to identify existing and at-risk NCD cases. The model also integrates a follow-up mechanism, ensuring patients adhere to treatment regimens, adopt lifestyle modifications, and are referred to government hospitals in case of complications. An analysis by HHF of over 12,000 patient records from urban settlements revealed that 45% of patients find travelling to public health centres both expensive and inconvenient. As a result, about 50% were found to be irregular with treatment, increasing their risk of complications. 'Years of deprivation and weak access to healthcare have led to poor health-seeking behaviour among these communities,' said Mujtaba Hasan Askari of HHF. Preliminary findings from a door-to-door survey of 500 residents, 70% women and 30% men have highlighted the scale of the problem. Around 41% of those surveyed were found to have NCDs. Within this group, 43% had diabetes, 30% had hypertension, 15% had thyroid disorders, 5% had coronary artery disease, and 2.5% were newly diagnosed with diabetes. Alarmingly, nearly 60% of diabetes and hypertension cases were found to be uncontrolled, said the data shared by HHF. The survey also showed that 38% of the NCD patients were obese, with two-thirds of them suffering from both diabetes and hypertension. Another 32% were overweight, and half of these individuals were diagnosed with NCDs. Beyond diabetes and hypertension, patients will be periodically screened for a range of other health issues including eye disorders, oral health, kidney disease, non-alcoholic fatty liver disease, dementia, and cancers of the breast, cervix, and oral cavity, all at no cost. Provision of spectacles and cataract surgeries will also be free, added Mr. Askari.
The Hindu
3 hours ago
- The Hindu
‘PrYAAS': 37,800 children to undergo speech, hearing tests in Karnataka's Chamarajanagar
The Chamarajanagar district administration, in collaboration with the Departments of Women and Child Development, and Health and Family Welfare, and the Mysuru-based All India Institute of Speech and Hearing (AIISH), has launched the Programme for Assessment of Young Children for Auditory and Speech-Language Skills (PrAYAAS) in the Karnataka district on Friday. Minister in charge of the district K. Venkatesh, who is also the Animal Husbandry and Sericulture Minister, launched the initiative at an anganwadi in ward no. 10 of Karinanjanapura Layout. The initiative focuses on speech (vocal) and hearing tests for anganwadi children. After launching the programme and wishing success to the scheme, Mr. Venkatesh reviewed the screening process that began for the children. Appreciating the initiative, MLA for Chamarajanagar C. Puttarangashetty said that the programme is being implemented for the first time in the State by the Chamarajanagar district administration, and described it as a progressive step for supporting the learning processes of children. Deputy Commissioner Shilpa Nag said that parents often notice their child's inability to hear or speak clearly only at a later stage, and poor families in rural areas may not be able to afford treatment. Therefore, the district administration partnered with AIISH Mysuru to provide free medical services for all children aged between six months and six years, she added. The programme identifies and treats speech and hearing problems among anganwadi children at an early stage and also trains anganwadi workers to recognise early symptoms of speech and hearing impairment. It also aims to develop a comprehensive plan of action to provide screening and treatment facilities at the district hospital for affected persons. The district has 440 anganwadis with about 37,800 children. Of these, the target for the current year is to screen 35,326 children. The programme has been launched symbolically, and training for anganwadi workers by master trainers will be conducted next month. The scheme will then be rolled out across all anganwadis in the district, the Deputy Commissioner informed. According to AIISH, research indicates that about 14% of children are at a risk of having speech, language, or hearing difficulties, which, if left unaddressed, can hinder their overall development. In view of this, PrAYAAS aims to identify all such children aged 6 months to 6 years across the district and provide timely interventions. Screening will be carried out by experienced speech-language pathologists and audiologists from AIISH and ENT surgeons from the District Hospital. Conditions such as speech delays, mispronunciations, stammering, voice disorders, lack of social interaction, hearing loss, and ear infections will be assessed, a press release from AIISH said. The initiative, scheduled to run until March 31, 2026, will be implemented in five phases.
Time of India
13 hours ago
- Time of India
Investors see growth in single-specialty hospitals
Representative image NEW DELHI: With traditional multi-specialty hospital chains nearing deal saturation, investors are increasingly shifting their focus on single-specialty hospitals (SSHs), which are fast emerging as the next growth frontier in India's healthcare landscape. Offering focused care, operational efficiency and faster scalability, SSHs have become particularly attractive to private equity (PE) firms, analysts told TOI. This shift is reflected in deal activity: SSHs now account for over half of all hospital transactions by volume, supported by $2.3 billion in PE investments over the past three years, according to data from Grant Thornton Bharat. Over the past decade, deal volumes in India's single-specialty hospital segment remained steady, peaking in 2023. The year 2023 saw the highest deal value of $1.2 billion, largely driven by landmark transactions such as BPEA EQT's investment in Indira IVF and Quadria's strategic investments in Maxivision and NephroPlus. Next growth frontier Sunil Thakur, partner at Quadria Capital, says, "Projected to more than double to $9 billion by 2028, organised single-specialty networks offer compelling economics, (>20% earnings before interest, taxes, depreciation, and amortisation, 20-25% return on capital employed) powered by deep specialisation and rapid access expansion. The momentum is evident from the fact that over $3.5 billion of PE capital has flowed into the segment in recent years. " The segment is growing at a robust 24% annually - outpacing the 15-17% growth seen in multi-specialty counterparts -indicating strong investor confidence. Key specialties driving this growth include, in vitro fertilisation (IVF), women's and child care, eye care, nephrology, and oncology - each witnessing substantial deal activity. "Investor interest in the segment has remained consistent, though we are yet to see a large-value deal in 2025. Strong fundamentals, including healthy margins, better unit economics, scalability, asset-light models, and quicker break-even cycles, continue to attract both strategic and financial investors. As healthcare delivery expands beyond metro cities, single-specialty formats are increasingly seen as effective platforms for regional growth," says Bhanu Prakash Kalmath SJ, Partner and Healthcare Leader, Grant Thornton Bharat. Valued at approximately $15 billion, the SSH market includes an organised segment worth around $4 billion, which continues to gain scale through consolidation and network expansion. The focus on single-specialty hospitals is a global phenomenon, reflecting a broader shift towards specialised, efficient healthcare delivery, experts say. Vishal Bali, executive chairman Asia Healthcare Holdings, a platform focused on single-specialty hospitals, backed by TPG and Singapore-based GIC, says: "We strongly believe that one of the key prescriptions to bridge India's demand-supply gap in healthcare delivery sits with SSH enterprises." Stay informed with the latest business news, updates on bank holidays , public holidays , current gold rate and silver price .
